PMID- 29102053
OWN - NLM
STAT- MEDLINE
DCOM- 20171229
LR  - 20171229
IS  - 1097-6787 (Electronic)
IS  - 0190-9622 (Linking)
VI  - 78
IP  - 1
DP  - 2018 Jan
TI  - Depressive symptoms, depression, and the effect of biologic therapy among 
      patients in Psoriasis Longitudinal Assessment and Registry (PSOLAR).
PG  - 70-80
LID - S0190-9622(17)32316-2 [pii]
LID - 10.1016/j.jaad.2017.08.051 [doi]
AB  - BACKGROUND: Patients with psoriasis are at an increased risk for depression. 
      However, the impact of treatment on this risk is unclear. OBJECTIVE: Evaluate the 
      incidence and impact of treatment on depression among patients with 
      moderate-to-severe psoriasis. METHODS: We defined a study population within the 
      Psoriasis Longitudinal Assessment and Registry and measured the incidence of 
      depressive symptoms (Hospital Anxiety and Depression Scale-Depression score >/=8) 
      and adverse events (AEs) of depression within cohorts receiving biologics, 
      conventional systemic therapies, or phototherapy. Patients were evaluated at 
      approximately 6-month intervals. Multivariate modeling determined the impact of 
      treatment on risk. RESULTS: The incidence rates of depressive symptoms were 3.01 
      per 100 patient-years (PYs) (95% confidence interval [CI], 2.73-3.32), 5.85 per 
      100 PYs (95% CI, 4.29-7.97), and 5.70 per 100 PYs (95% CI, 4.58-7.10) for 
      biologics, phototherapy, and conventional therapy, respectively. Compared with 
      conventional therapy, biologics reduced the risk for depressive symptoms (hazard 
      ratio, 0.76; 95% CI, 0.59-0.98), whereas phototherapy did not (hazard ratio, 
      1.05; 95% CI, 0.71-1.54). The incidence rates for AEs of depression were 0.21 per 
      100 PYs (95% CI, 0.15-0.31) for biologics, 0.55 per 100 PYs (95% CI, 0.21-1.47) 
      for phototherapy, and 0.14 per 100 PYs (95% CI, 0.03-0.55) for conventional 
      therapy; the fact that there were too few events (37 AEs) precluded modeling. 
      LIMITATIONS: Incomplete capture of depression and confounders in the patients on 
      registry. CONCLUSION: Compared with conventional therapy, biologics appear to be 
      associated with a lower incidence of depressive symptoms among patients with 
      psoriasis.
CI  - Copyright (c) 2017 American Academy of Dermatology, Inc. Published by Elsevier Inc. 
      All rights reserved.
FAU - Strober, Bruce
AU  - Strober B
AD  - University of Connecticut Health Center, Farmington, Connecticut; Probity Medical 
      Research, Waterloo, Ontario, Canada. Electronic address: strober@uchc.edu.
FAU - Gooderham, Melinda
AU  - Gooderham M
AD  - Queen's University, Kingston, Ontario, Canada; SKiN Centre for Dermatology, 
      Peterborough, Ontario, Canada.
FAU - de Jong, Elke M G J
AU  - de Jong EMGJ
AD  - Radboud University Medical Center and Radboud University, Nijmegen, The 
      Netherlands.
FAU - Kimball, Alexa B
AU  - Kimball AB
AD  - Beth Israel Deaconess Hospital and Harvard Medical School, Boston, Massachusetts.
FAU - Langley, Richard G
AU  - Langley RG
AD  - Dalhousie University, Halifax, Nova Scotia, Canada.
FAU - Lakdawala, Nikita
AU  - Lakdawala N
AD  - Medical College of Wisconsin, Milwaukee, Wisconsin.
FAU - Goyal, Kavitha
AU  - Goyal K
AD  - Janssen Scientific Affairs, LLC, Horsham, Pennsylvania.
FAU - Lawson, Fabio
AU  - Lawson F
AD  - Janssen Scientific Affairs, LLC, Horsham, Pennsylvania.
FAU - Langholff, Wayne
AU  - Langholff W
AD  - Janssen Research & Development, LLC, Spring House, Pennsylvania.
FAU - Hopkins, Lori
AU  - Hopkins L
AD  - Janssen Scientific Affairs, LLC, Horsham, Pennsylvania.
FAU - Fakharzadeh, Steve
AU  - Fakharzadeh S
AD  - Janssen Scientific Affairs, LLC, Horsham, Pennsylvania.
FAU - Srivastava, Bhaskar
AU  - Srivastava B
AD  - Janssen Scientific Affairs, LLC, Horsham, Pennsylvania.
FAU - Menter, Alan
AU  - Menter A
AD  - Baylor University Medical Center at Dallas, Dallas, Texas.
LA  - eng
PT  - Journal Article
DEP - 20171106
PL  - United States
TA  - J Am Acad Dermatol
JT  - Journal of the American Academy of Dermatology
JID - 7907132
RN  - 0 (Biological Products)
SB  - IM
MH  - Adult
MH  - Age Factors
MH  - Biological Products/pharmacology/*therapeutic use
MH  - Comorbidity
MH  - Depression/diagnosis/*epidemiology
MH  - Depressive Disorder/diagnosis/epidemiology
MH  - Female
MH  - Humans
MH  - Incidence
MH  - Longitudinal Studies
MH  - Male
MH  - Middle Aged
MH  - Phototherapy/methods
MH  - Prognosis
MH  - Proportional Hazards Models
MH  - Psoriasis/diagnosis/*psychology/*therapy
MH  - *Quality of Life
MH  - *Registries
MH  - Risk Assessment
MH  - Severity of Illness Index
MH  - Sex Factors
MH  - United States/epidemiology
OTO - NOTNLM
OT  - PSOLAR
OT  - biologic therapy
OT  - depression
OT  - phototherapy
OT  - psoriasis
OT  - systemic therapy
EDAT- 2017/11/06 06:00
MHDA- 2017/12/30 06:00
CRDT- 2017/11/06 06:00
PHST- 2017/06/22 00:00 [received]
PHST- 2017/08/18 00:00 [revised]
PHST- 2017/08/24 00:00 [accepted]
PHST- 2017/11/06 06:00 [pubmed]
PHST- 2017/12/30 06:00 [medline]
PHST- 2017/11/06 06:00 [entrez]
AID - S0190-9622(17)32316-2 [pii]
AID - 10.1016/j.jaad.2017.08.051 [doi]
PST - ppublish
SO  - J Am Acad Dermatol. 2018 Jan;78(1):70-80. doi: 10.1016/j.jaad.2017.08.051. Epub 
      2017 Nov 6.